



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PF-06426779

Cat. No.:	HY-123854
CAS No.:	1817628-40-2
Molecular Formula:	C ₁₇ H ₁₈ FN ₃ O ₄
Molecular Weight:	347.34
Target:	IRAK
Pathway:	Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (287.90 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.8790 mL	14.3951 mL	28.7902 mL
		5 mM		0.5758 mL	2.8790 mL	5.7580 mL
		10 mM		0.2879 mL	1.4395 mL	2.8790 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (5.99 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	PF-06426779 is a potent and selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), with an IC ₅₀ of 0.3 nM [1].
IC ₅₀ & Target	IRAK4 0.3 nM (IC ₅₀)
In Vitro	PF-06426779 inhibits IRAK4, with an IC ₅₀ of 12.7 nM in the peripheral blood mononuclear cells (PBMCs) assay [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lee KL, et, al. Discovery of Clinical Candidate 1-[[[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy]-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13; 60(13): 5521-5542.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA